Recombinetics provides gene editing solutions for biomedical research, regenerative medicine, and animal agriculture. The company utilizes its proprietary gene editing platform to develop technologies that impact human health and enhance farm animal value.

Recombinetics

Recombinetics is involved in animal gene editing and associated technologies for biomedical research, regenerative medicine, and animal agriculture, self-described as a leader in these fields.

Recombinetics  | 2,157 followers on LinkedIn. Delivering the Next Evolution of Healthcare

 | Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

Led by a team of expert geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St.

Legal and HR Manager at Recombinetics

Nikki Rockstroh, MnCP

Experienced General Counsel & Corporate Secretary | JD, Six Sigma

John Burtis

CFO RCI

Justin Zenanko

Quality Control Supervisor at Recombinetics, Inc.

Ashley Lokensgard

Beta testers wanted: Recombinetics is looking for users of iPSCs to help test our cells and robust growth media. Would your research benefit from the availability of Porcine Pluripotent Stem Cells? At Recombinetics we specialize in gene editing, animal reproduction, and cell manufacturing. With this we have derived and characterized both porcine induced pluripotent and embryonic stem cell lines that are stable for well over 60 passages and counting. We are seeking a handful of beta testers to evaluate how the cells perform in different labs and applications. If this is something you are interested in or would like more information, please contact info@Recombinetics.com or see our website at www.Recombienetics.com #betatest #iPSCs #geneediting #regenativemedicine #stemcells

We’re in Baltimore for ASGCT 2024! Stop by poster #517 on Wednesday, May 8th at 5:30 EST to hear from Jarryd Campbell about our swine reporter models for somatic cell genome editing. We are looking forward to making some new connections and meeting up with old colleagues. #asgct #pigmodel #geneediting

Gene therapy continues to advance healthcare…

Recombinetics is excited to share the work our subsidiary, @Acceligen, has put together. Check out the note in the National Hog Farmer on the work done to generate PRRS resistant pigs. Porcine Respiratory and Reproductive Syndrome (PRRS) is a constant concern for pork production. The scientific information can be found in our paper published in collaboration with Rowland, Robert in the journal of Antiviral Research.

RECO

COM:RECOMBINETICS

Recombinetics

locale

market

industry

website

crunchbase

linkedin

peer of

Metrics